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Introduction: Despite growing evidence that large intergenic noncoding RNAs (lincRNAs) can regulate gene
expression and widely take part in normal physiological and disease conditions, our knowledge of systemic
lupus erythematosus (SLE)-related lincRNAs remains limited. The aim of this study was to detect the levels of
four lincRNAs (ENST00000500949: linc0949, ENST00000500597: linc0597, ENST00000501992: linc1992, and
ENST00000523995: linc3995) involved in innate immunity in the peripheral blood mononuclear cells (PBMCs)
of patients with SLE and correlate these lincRNA levels with disease activity, organ damage, clinical features and
medical therapies.
Methods: PBMCs were obtained from 102 patients with SLE, 54 patients with rheumatoid arthritis (RA) and 76
healthy donors. lincRNA expression levels were measured by real-time quantitative polymerase chain reaction.
Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
scores, and organ damage was evaluated with the Systemic Lupus International Collaborating Clinics/American
College of Rheumatology Damage Index.
Results: linc0949 and linc0597 were significantly decreased in patients with SLE compared with patients with RA
and healthy control subjects. linc0949 was correlated with SLEDAI-2K score (r = −0.329, P = 0.0007), as well as with
complement component C3 level (r = 0.348, P = 0.0003). The level of linc0949 was also reduced in patients with SLE
who had the presence of cumulative organ damage. In addition, decreasing expression of linc0949 was associated
with lupus nephritis. linc0949 expression significantly increased after treatment, whereas neither disease activity nor
organ damage correlated with linc0597 expression.
Conclusions: Our results provide novel empirical evidence that linc0949 could be a potential biomarker for
diagnosis, disease activity and therapeutic response in SLE.Introduction
Systemic lupus erythematosus (SLE) is a systemic auto-
immune disease with various clinical manifestations affect-
ing different tissues. It is characterized by the deposition
of immune complexes due to widespread loss of immune
tolerance to nuclear self-antigens, as well as by excessive
proinflammatory cytokine production and damage to mul-
tiple organ systems [1]. Recent experimental and clinical* Correspondence: tangyuanjia028@163.com; nanshensibs@gmail.com
1Shanghai Institute of Rheumatology, Department of Rheumatology, Renji
Hospital, School of Medicine, Shanghai Jiao Tong University, Shan Dong
Middle Road, Shanghai 200001, People’s Republic of China
Full list of author information is available at the end of the article
© 2015 Wu et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.studies have placed new emphasis on the role of the innate
immune system in SLE. It has become apparent that Toll-
like receptors (TLRs) can participate in cell activation by
self molecules such as immune complexes containing
DNA or RNA. Indeed, TLRs have an important role in
the pathogenesis of lupus involving recruitment of adapter
proteins; activation of protein kinases and transcription
factors; and expression of inflammatory cytokines, chemo-
kines, endothelial adhesion molecules and costimulatory
molecules [2]. TLR signaling also stimulates B cell pro-
liferation, cell differentiation and immunoglobulin class
switching [2,3].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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RNAs has been emphasized in many biological and patho-
logical processes [4]. Much research has been focused on
microRNAs (miRNAs). miRNAs are small RNA molecules
with a length of approximately 22 nucleotides (nt) that
play a critical role in the pathogenesis of SLE by regulating
gene expression at posttranscriptional levels [5,6]. miR-
NAs have also been reported to be involved in the local
inflammatory response that ultimately leads to tissue in-
jury and organ damage [7]. Recently, several studies have
shown the feasibility of using miRNAs as biomarkers in
body fluids for the diagnosis of SLE [8-10]. Though miR-
NAs play important roles in SLE, they are only a small
fraction of the noncoding regions of the mammalian gen-
ome. Unlike miRNAs, long noncoding RNAs (lncRNAs)
are expressed abundantly, including large intergenic non-
coding RNAs (lincRNAs) [11].
lncRNAs are a class of mRNA-like transcripts ranging
in length from 200 nt to over 100 kb and lacking any sig-
nificant open reading frames [12,13]. They are highly di-
verse and actively present in virtually every aspect of cell
biology, such as cell differentiation, cell proliferation, DNA
damage response, dosage compensation and chromosomal
imprinting. Recently, a number of lncRNA molecules have
been reported to be involved in diverse diseases [14-16].
Some evidence indicates that a few samples of lncRNAs
could regulate the immune system [17-19]. In particular,
there are several emerging hypotheses on lncRNA involve-
ment in rheumatic diseases, such as rheumatoid arthritis
(RA) [20,21], autoimmune thyroid disease [22] and
psoriasis [23]. Other preliminary data in a murine model
system pointed to a link between the lncRNA growth ar-
rest–specific 5 (GAS5) and disease susceptibility to SLE
[16]. In addition, the chromosomal locus of GAS5, 1q25,
was showed to be associated with human SLE develop-
ment in genetic studies [23-25].
Because of the heterogeneous presentation of patients
with SLE and their unpredictable disease course, there is
a pressing need to identify biomarkers that will facilitate
better diagnosis and prognosis, and lincRNAs as bio-
markers are still largely unexplored in this regard. It has
been reported that four lincRNAs (linc0949, linc0597,
linc1992 and linc3995) not only are differentially expressed
following innate activation of THP-1 macrophages but also
regulate induction of proinflammatory cytokines such as
tumor necrosis factor (TNF)-α and interleukin (IL)-6 [26].
Moreover, it is well-established that IL-6 and TNF-α are in-
volved in SLE pathogenesis [27-29].
As mentioned above, we hypothesized that these lincR-
NAs would produce cross-linking with SLE via innate im-
munity and play a critical role in the pathogenesis of SLE
and that they might serve as biomarkers of disease activity,
organ damage and medical response. In the present study,
we aimed to investigate whether the expression levels ofthese lincRNAs in peripheral blood mononuclear cells
(PBMCs) were abnormal in patients with SLE, assess the
relationship of the levels with disease activity and organ
damage, and explore new biomarkers used in disease
monitoring and prognostication.
Methods
Patients and healthy controls
All samples from patients with SLE and patients with
RA were obtained from the Department of Rheumatology
of Renji Hospital (Shanghai, China). All patients with SLE
met at least four of the American College of Rheumatology
(ACR) 1982 revised criteria for SLE [30]. Patients with RA
were diagnosed according to the ACR/European League
Against Rheumatism 2010 classification criteria for RA
[31]. The control group comprised healthy volunteers with
no history of autoimmune disease or immunosuppressive
therapy. Otherwise eligible individuals with a current or re-
cent infection were excluded from the study. Control sub-
jects were frequency-matched with the patients for age and
sex. All participants were from the Han Chinese popula-
tion. The study was approved by the Research Ethics Board
of Renji Hospital, Shanghai Jiao Tong University School of
Medicine, Shanghai, China. Informed consent was ob-
tained from all study participants.
The patients with lupus were all receiving steroid therapy
at the time of the study, and a prednisone dosage per day
(dosages of other steroids were converted to prednisone
equivalents) from 2.5 mg to 500 mg (mean dosage:
29.5 mg/day). In addition, 42 patients were receiving im-
munosuppressive therapy (azathioprine (AZA; n = 7), cyclo-
phosphamide (CYC; n = 10), cyclosporine A (CsA; n = 6),
tacrolimus (FK506; n = 1), leflunomide (LEF; n = 2), myco-
phenolate mofetil (MMF; n = 8), methotrexate (MTX; n =
8)), and 59 were receiving an antimalarial drug (chloro-
quine or hydrochloroquine). For each patient, the severity
of disease was assessed with the Systemic Lupus Erythema-
tosus Disease Activity Index 2000 (SLEDAI-2K) [32]. Organ
damage (defined as nonreversible change, not related to ac-
tive inflammation, occurring since the onset of lupus and
present for at least 6 months) was assessed using the Sys-
temic Lupus International Collaborating Clinics/American
College of Rheumatology Damage Index (SDI) score [33].
In our cohort, nearly 51.0% of patients (52 of 102 patients
with SLE) had either previous or current lupus nephritis
(LN) (Table 1). Subjects were considered to have active
renal disease if proteinuria was ≥0.5 g/day, hematuria was
≥5 red blood cells per high-power field (hpf), pyuria was ≥5
white blood cells/hpf or cellular casts were present. Infec-
tion, kidney stones and other causes were excluded.
Peripheral blood samples handling and RNA processing
Peripheral blood samples (10 ml) were obtained from each
subject. The samples were collected in tubes containing
Table 1 Large intergenic noncoding RNA linc0949 by presence or absence of clinical features of systemic lupus
erythematosusa
Clinical features SLE clinical features present SLE clinical features absent P-value
N Mean ± SEM (range, 10−3) N Mean ± SEM (range, 10−3)
Renal 50 2.16 ± 0.152 52 1.47 ± 0.132 0.0014
Rash 33 1.89 ± 0.200 69 1.87 ± 0.199 NS
Arthritis 35 1.79 ± 0.327 67 1.97 ± 0.163 NS
Serositis 21 1.81 ± 0.307 81 1.72 ± 0.364 NS
Mucosal ulcer 19 2.02 ± 0.207 83 1.87 ± 0.187 NS
Hematologic 30 1.84 ± 0.243 72 2.06 ± 0.179 NS
Neurologic 9 1.99 ± 0.084 93 2.05 ± 0.45 NS
Autoantibodies
Anti-dsDNA 40 1.91 ± 0.274 62 1.88 ± 0.264 NS
Anti-Sm 16 2.07 ± 0.202 86 1.78 ± 0.193 NS
Anti-nucleosome 40 1.91 ± 0.204 62 1.88 ± 0.212 NS
Anti-SSA/SSB 32 2.03 ± 0.258 70 2.01 ± 0.176 NS
Anti-RNP 22 1.95 ± 0.253 80 1.96 ± 0.165 NS
Medical therapy
Prednisone dose ≥30 mg/day 48 2.08 ± 0.175 54 1.94 ± 0.181 NS
Immunosuppressantsb 42 2.00 ± 0.141 60 1.54 ± 0.151 0.0365
adsDNA, Double-stranded DNA; NS, Not significant; RNP, Ribonucleoprotein; SEM, Standard error of the mean; SLE, Systemic lupus erythematosus; Sm, Smith; SSA,
Sjögren’s syndrome–related antigen A; SSB, Sjögren’s syndrome–related antigen B. bImmunosuppressants included azathioprine, cyclophosphamide, cyclosporine
A, FK506 (tacrolimus), leflunomide, mycophenolate mofetil and methotrexate.
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lated from anticoagulated whole blood by use of Ficoll
density gradient centrifugation. Then total RNA was ex-
tracted from PBMCs using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA). The integrity of the RNA was
assessed using capillary gel electrophoresis, and the
concentrations of RNA were measured using a Nano-
Drop™ 1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA) with a 260 nm/280 nm ratio above
1.8. About 200 ng of total RNA were reverse-transcribed
into cDNA using a PrimeScript RT reagent kit (Takara
Bio, Dalian, China). All RNA and cDNA samples were
stored at −70°C before use.Cell culture and stimulation
Peripheral blood samples were obtained from five
healthy donors and five patients with SLE. The samples
were collected in tubes containing EDTA. PBMCs were
isolated from anticoagulated whole blood by Ficoll
density gradient centrifugation. Two hours before
stimulation, 1 × 106 PBMCs were cultured in 24-well
flat-bottomed plates in 500 μl of RPMI 1640 medium
containing 10% fetal bovine serum (FBS). Then the
PBMCs were stimulated for 4 hours with the TLR2 lig-
and Pam3CK4 (20 ng/ml).Cell culture and treatment with dexamethasone and
immunosuppressant agents
Peripheral blood samples were obtained from two healthy
donors. PBMCs were isolated from anticoagulated whole
blood by use of Ficoll density gradient centrifugation. PBMCs
(1 × 106) were resuspended for 2 hours in 500 μl of RPMI
1640 medium containing 10% FBS, then dexamethasone was
added with the indicated concentration (Dexamethasone
concentrations were 10ng/ml,100ng/ml,1000ng/ml,10ug/ml,
respectively) for another 24 hours, as were CsA (200 nmol)
and FK506 (20 nmol). RNA samples were then isolated, and
real-time quantitative PCRs (RT-qPCRs) were performed.Real-time quantitative polymerase chain reaction
To quantify the expression of four lincRNAs (linc0949,
linc0597, linc1992 and linc3995), cDNA was amplified by
RT-PCR with SYBR Green (SYBR Premix Ex Taq RT-PCR
kit; Takara Bio). The primer sequences used for SYBR
Green–based RT-PCR are given in Table 2. The ribosomal
protein L13A (RPL13A) gene was used as an internal con-
trol to normalize the amounts of cDNA. The SYBR Green
assays were performed in duplicate using an ABI ViiA 7
Real-Time PCR System (Applied Biosystems, Foster City,
CA, USA). The relative expression levels were calculated
using the 2−ΔCt comparative threshold cycle method.







aThe four large intergenic noncoding RNAs primers are derived from the literature [26].
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Data were analyzed with GraphPad Prism version 5.0
software (GraphPad Software, La Jolla, CA, USA). The
nonparametric Mann–Whitney U test was used to com-
pare gene expression between two groups. The correl-
ation between groups was evaluated using Spearman’s
rank correlation coefficient test. The strength of the cor-
relation was graded using Cohen’s criteria as follows: 0.3
to 0.5 = weak, 0.5 to 0.7 =moderate and >0.7 = strong
[34]. P-values (two-tailed) <0.05 were considered statisti-
cally significant.
Results
Decreased linc0949 and linc0597 levels in patients with
systemic lupus erythematosus
The expression levels of four lincRNAs (linc0949, linc0597,
linc1992 and linc3995) in PBMCs taken from 102 patients
with SLE, 54 patients with RA and 76 healthy donors were
measured using RT-qPCR. Patients with SLE and healthy
donors did not differ significantly with respect to mean age
or sex distribution (Table 3). The average disease duration
of patients enrolled in our study was 4.98 years for those
with SLE and 5.12 years for those with RA. In general, the
patients with SLE had mild to moderate flares of disease
activity and severity, with a mean SLEDAI-2K score of 7
and a mean SDI of 0.78 (Table 3).
As shown in Figure 1A, patients with SLE had signifi-
cantly lower linc0949 levels than healthy donors and
patients with RA (both P < 0.0001). Also, the expression
of linc0597 was decreased dramatically in patients withTable 3 Demographic dataa
Patients with SLE (n = 102)




Disease duration (yr) 4.98 ± 0.76 (0.04 to 28)
ANA (%) 95.0
SLEDAI-2K 6.82 ± 0.52 (1 to 15)
SDI 0.78 ± 0.14 (0 to 3)
aANA, antinuclear antibody; RA, Rheumatoid arthritis; SDI, Systemic Lupus Internatio
SLE, Systemic lupus erythematosus; SLEDAI-2K, Systemic Lupus Erythematosus DiseSLE compared with healthy donors and patients with RA
(P = 0.0001 and P < 0.0001, respectively) (Figure 1B).
Figure 1C and Figure 1D, however, show no significant
differences in linc1992 and linc3995 levels between pa-
tients with SLE and healthy donors or patients with RA.
These results revealed that lower expression of linc0949
and linc0597 was specific to SLE, so we selected these
lincRNAs for further research.Association of linc0949 level with disease activity in
patients with systemic lupus erythematosus
To investigate whether the expression of linc0949 and
linc0597 is related to SLE disease activity, we compared
the relative expression levels of the lincRNAs in patients
with SLE with different levels of disease activity, assessed
on the basis of SLEDAI-2K score and the level of com-
plement C3. In accordance with the SLEDAI-2K flare
system, patients with SLE were divided into those with
stable disease (SLEDAI-2K scores from 0 to 4), those
with a mild flare (SLEDAI-2K scores from 5 to 10) and
those with a moderate to severe disease flare (SLEDAI-
2K scores >10). linc0949 was significantly lower in patients
with SLE who had a mild flare or a moderate to severe
flare of disease than in patients without a flare (P = 0.0032
and P = 0.0004, respectively) (Figure 2A). In addition, a
correlation between linc0949 and SLEDAI-2K score was
observed in that decreased levels of linc0949 coincided
with increased SLEDAI-2K score in patients with SLE
(r = −0.329, P = 0.0007) (Figure 2B).Patients with RA (n = 54) Healthy donors (n = 76)
38.7 ± 2.3 (20 to 65) 34.0 ± 1.2 (20 to 63)
46 70
8 6




nal Collaborating Clinics/American College of Rheumatology Damage Index;
ase Activity Index 2000 score.
Figure 1 Comparison of expression of four large intergenic noncoding RNAs (linc0949, linc0597, linc1992 and linc3995) between patients with SLE,
patients with RA and healthy donors. Each symbol represents an individual patient; horizontal lines indicate median values. The expression levels
of the four large intergenic noncoding RNAs (lincRNAs) in 102 patients with SLE, 54 patients with RA and 76 healthy donors were analyzed by
real-time quantitative PCR and normalized by RPL13A level. (A) Decreased expression of linc0949 in patients with SLE versus patients with RA and
healthy donors. (B) linc0597 expression was significantly reduced in patients with SLE versus patients with RA and healthy donors. No apparent
difference was detected in the expression of linc1992 (C) and linc3995 (D) between patients with SLE, patients with RA and healthy donors. NS,
Not significant. ***P < 0.001. HD, Healthy donors; RA, Rheumatoid arthritis; SLE, Systemic lupus erythematosus.
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complementemia is often observed in patients with SLE
with active disease. In the present research, linc0949 ex-
pression was significantly decreased in patients with SLE
who had a reduced level of complement C3 (<80 mg/dl)
compared with those with normal levels of C3 (P < 0.0001)
(Figure 2C). Further analysis revealed a positive correl-
ation between linc0949 level and C3 level (r = 0.348, P =
0.0003) (Figure 2D). However, the level of linc0597 did not
correlate with SLEDAI-2K and complement C3 level (data
not shown). These results indicate that the abnormal ex-
pression of lincRNA0949 may be a key indicator of disease
activity in patients with SLE.
Reduced expression of linc0949 in patients with systemic
lupus erythematosus with organ damage
SLE is a chronic multisystem autoimmune disease that
can affect virtually every organ system and may lead to
significant morbidities. Assuming that lincRNAs are in-
volved in tissue damage and inflammation, we investigated
whether linc0949 and linc0597 were associated with differ-
ent levels of chronic and irreversible organ damage in the
patients with SLE. The results revealed significantly lowerlevels of linc0949 in patients with SLE with SDI scores of
1 to 2 and in those with scores >2 versus those without
organ damage (P = 0.0059 and P = 0.0009, respectively)
(Figure 3A). linc0597 expression was not significantly re-
duced in patients with organ damage (SDI ≥1) versus
those who remained damage-free (data not shown).
LN is one of the most common clinical manifestations
and causes of organ damage in patients with SLE, so we
wanted to know whether lincRNA levels are related to
LN. In our cohort, nearly 51% of patients (52 of 102
patients with SLE) had either previous or current LN
(Table 1). Patients with LN had lower linc0949 expres-
sion levels than those without renal manifestations (P =
0.0014) (Figure 3B). Expression levels of linc0949 were
decreased in the group of patients with active LN com-
pared with those without LN (P = 0.0009) (Figure 3C),
whereas linc0949 levels were not significantly different
in patients with inactive LN compared with patients
without LN at the time of blood drawing (P = 0.0739)
(Figure 3C). These data suggest that linc0949 expression
is related with cumulative organ damage in SLE and that
linc0949 may be useful in predicting long-term outcome
and prognosis in patients with SLE.
Figure 2 Association of large intergenic noncoding RNA linc0949 expression with disease activity in patients with systemic lupus erythematosus.
(A) Patients with systemic lupus erythematosus (SLE) with a moderate to severe flare of disease (Systemic Lupus Erythematosus Disease Activity
Index 2000 (SLEDAI-2K) score >10) or a mild flare of disease (SLEDAI-2K score from 5 to 10) had significantly lower large intergenic noncoding
RNA linc0949 expression than did those without a disease flare (SLEDAI-2K score <4) at the time of blood donation. (B) linc0949 expression
was negatively correlated with SLEDAI-2K score. (C) linc0949 expression was significantly decreased in patients with SLE with a reduced level of
complement C3 (<80 mg/dl) compared with those with normal C3levels. (D) A significantly positive correlation was observed between linc0949
expression and C3 level in patients with SLE. **P < 0.01, ***P < 0.001.
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with clinical manifestations and medical therapies
To assess the association between lincRNA levels and
clinical manifestations, autoantibody profiles and med-
ical treatments, linc0949 and linc0597 levels were com-
pared between patients with certain clinical features andFigure 3 Large intergenic noncoding RNA linc0949 expression was decreas
damage. (A) In our cohort, linc0949 was dramatically decreased in patients wi
organ damage (Systemic Lupus International Collaborating Clinics/American C
compared with those with no damage. (B) Large intergenic noncoding RN
lupus nephritis (LN; n = 52) relative to patients with no history of LN (n = 5
those without renal manifestations, whereas linc0949 level was not signific
without LN. NS, Not significant. **P < 0.01, ***P < 0.001.those without certain clinical features. We identified no
association between linc0949 or linc0597 expression and
clinical manifestations such as rash, arthritis, serositis, mu-
cosal ulcer, hematologic involvement or neurologic mani-
festations (linc0949: Table 1; linc0597: data not shown).
We also found that neither linc0949 nor linc0597 appeareded in patients with systemic lupus erythematosus who had organ
th systemic lupus erythematosus (SLE) who had chronic and irreversible
ollege of Rheumatology Damage Index (SDI) scores 1 to 2 or more)
A linc0949 expression exhibited a decreasing trend in patients with
0). (C) Patients with active LN had lower linc0949 expression than
antly different in patients with inactive LN compared with those
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ing anti-double-stranded DNA, anti-Smith antibodies,
antinucleosome antibodies, anti–Sjögren’s syndrome–
related antigen A and B antibodies and antiribonucleo-
protein antibodies (linc0949: Table 1; linc0597: data not
shown).
When medical therapies were considered, the expres-
sion of linc0949 exhibited no significant difference in pa-
tients receiving medium to high doses of prednisone
(>30 mg/day) compared with patients treated with low
doses of prednisone (Figure 4A). By contrast, the expres-
sion of linc0949 in patients with SLE being treated with
immunosuppressants (AZA, CYC, CsA, LEF, MMF, MTX
and FK506) was significantly reduced compared with
those not receiving immunosuppressants at the time of
blood donation (P = 0.0365) (Figure 4B).
We next sought to assess whether SLE disease activity
or antirheumatic drugs affect the expression of linc0949,
as it was found that some lncRNAs can be induced in
response to the anti-inflammatory agent dexamethasone
[35]. Thus, we treated PBMCs of two healthy donors
with different concentrations of dexamethasone, CsAFigure 4 Association of large intergenic noncoding RNA linc0949 level with
(A) The level of the large intergenic noncoding RNA linc0949 had no appa
whose daily dosage of prednisone was >30 mg compared with those who
decreased significantly in patients with SLE who had used immunosuppressa
mycophenolate mofetil, methotrexate, FK506) compared with those without
related to the use of drugs. The data are from two healthy donors. (D) linc
beginning of and after 12 weeks of treatment. As we observed, the linc094
achieved significant clinical improvement after treatment. *P < 0.05. DXM,and FK506. FoxP3 level was significantly reduced after
treatment (Additional file 1: Figure S1), which supported
the fact that dexamethasone and immunosuppressive
agents worked effectively in vitro. As shown in Figure 4C,
dexamethasone, CsA and FK506 did not affect the ex-
pression of linc0949. This result relates to the effects of
antirheumatic drugs on the expression of linc949, which
confirms that linc0949 is intrinsically underexpressed in
patients with SLE.
We next investigated whether linc0949 was responsive to
treatment and changes over time in conjunction with dis-
ease activity. We chose three patients with SLE(P1,P2,P3),
as described in Figure 4D, P1 and P3 had initial onset of
biopsy-proved type IV LN, P2 had neuropsychological
lupus, and their peripheral blood samples were collected at
both the beginning of treatment and after 12 weeks of
treatment. P1 and P3 used high-dose prednisone (1 mg/kg
per day) plus mycophenolate mofetil (1.5-2 g/day), whereas
P2 used repeated pulses of glucocorticoid (500 mg intra-
venous methylprednisolone per day) for three days and
then prednisone (1 mg/kg per day) plus monthly pulse of
cyclophosphamide (0.8 g/month). After treatment, all ofmedical therapies in patients with systemic lupus erythematosus.
rent difference in patients with systemic lupus erythematosus (SLE)
se daily dosage of prednisone was <30 mg. (B) linc0949 expression
nts (azathioprine, cyclophosphamide, cyclosporine A (CsA), leflunomide,
immunosuppressant treatment. (C) The expression of linc0949 was not
0949 expression was detected in three patients with active SLE at the
9 expression of all three patients was notably increased when they
Dexamethasone; NS, Not significant; Pred, Prednisone.
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urinary protein level dropping to less than 0.5 g/24 hour in
P1 and P3; and with cerebrospinal fluid inspection and
head MRI restoring to normal in P2. SLEDAI-2K score of
the three patients reduced to a stable level (Additional
file 1: Figure S1). In concordance with the clinical im-
provement, linc0949 expression in these three patients
also significantly increased (Figure 4D).
Abnormal regulation of lincRNAs during innate activation
of peripheral blood mononuclear cells in patients with
systemic lupus erythematosus
To investigate the different response to innate immunity
of linc0949 and linc0597 in healthy donors and patients
with SLE, we stimulated PBMCs from healthy donors
and patients with SLE with TLR2 ligands. We chose
TLR2 ligands because it was reported that linc0949 and
linc0597 were regulated in THP-1 macrophages follow-
ing Pam3CSK4 stimulation [26] and TLR2 was required
for the production of prototypical lupus autoantibodies
and the development of renal disease in murine lupus
[36,37]. To prepare cell samples, PBMCs obtained from
5 healthy donors and 5 patients with SLE were stimu-
lated with Pam3CSK4 for 4 hours. Then we performed
RT-qPCR to identify changes in lincRNA expression. In
PBMCs of healthy controls, linc0949 was suppressed
(Figure 5A), while linc0597 was increased (Figure 5B) after
treatment with Pam3CSK4. But in patients with SLE,
linc0949 and linc0597 could not response to the stimuli
compared with healthy donors (Figure 5A and B). TheseFigure 5 Regulation of large intergenic noncoding RNAs in peripheral bloo
intergenic noncoding RNA linc0949 was lower in untreated and stimulated
systemic lupus erythematosus (SLE) than in those of healthy controls. linc09
(20 ng/ml) in healthy controls, and it was not significantly different after tre
agonist Pam3CK4 (20 ng/ml) in PBMCs of healthy controls, whereas it did n
was significantly decreased in PBMCs of patients with SLE compared with h
shown are from five healthy donors and five patients with SLE after incuba
of the indicated RNAs is normalized to RPL13A levels (mean ± standard dev
performing unpaired t-tests. NS, Not significant. *P < 0.05; **P < 0.01.results demonstrated that lincRNAs were indeed involved
in the complex regulatory network of innate immunity.
Discussion
In recent years, an increasing body of evidence has
shown that lncRNAs play major biological roles in em-
bryogenesis, stem cell biology and cellular development
and show developmental and tissue-specific expression
patterns [11,38,39]. Studies have also suggested that
abnormal expression of lncRNAs might be associated
with numerous diseases, indicating that these RNAs may
open a new avenue for diagnostic and therapeutic targets
by recognition of their roles in human disease.
In the present study, we detected four lincRNAs
(linc0949, linc0597, linc1992 and linc3995) and investi-
gated the association between their expression levels and
specific clinical features of SLE. Two of these lincRNAs
(linc0949 and linc0597) were significantly decreased in
patients with SLE compared with healthy donors and
disease controls. linc0949 was associated with disease ac-
tivity, as assessed using the SLEDAI-2K score and C3
level in patients with SLE. Moreover, linc0949 expression
was reduced in patients with SLE with ongoing or cu-
mulative organ damage, as assessed based on SDI score
or the presence of active LN. linc0949 expression does
not participate in clinical manifestations other than LN,
which demonstrates that it has very good detection speci-
ficity for LN. Lower levels of linc0949 may thus be helpful
to identify patients with SLE who have active and severe
disease. To evaluate the effect of antirheumatic drugs ond mononuclear cells by Pam3CSK4. (A) Expression of the large
peripheral blood mononuclear cells (PBMCs) of patients with
49 was suppressed by the Toll-like receptor 2 (TLR2) ligand Pam3CK4
atment in patients with SLE. (B) linc0597 was upregulated by TLR2
ot respond to the stimuli in patients with SLE. linc0597 expression
ealthy controls both before stimulation and after treatment. The data
tion with the indicated stimuli for 4 hours. Real-time quantitative PCR
iation (SD)). Data are mean ± SD. P-values were determined by
Wu et al. Arthritis Research & Therapy  (2015) 17:131 Page 9 of 11the expression of linc949, we used in vitro studies to test
whether the addition of dexamethasone, CsA or FK506 to
cultured PBMCs would affect the expression of linc0949.
As shown in Figure 4C, these antirheumatic drugs did not
affect the expression of linc0949 in PBMCs, which con-
firmed that linc0949 was intrinsically underexpressed in
patients with SLE. linc0949 expression of three patients
with severe disease flares significantly increased after
treatment (Figure 4D), indicating that linc0949 might be
responsive to treatment and might change in conjunc-
tion with disease activity and severity and suggesting
that linc0949 might be used to monitor disease progres-
sion and guide therapy.
Over the past several decades, tremendous enthusiasm
and efforts have been devoted to biomarkers for SLE
because the diagnosis of SLE requires a combination of
clinical manifestations and biomarkers and no single test
is sufficiently sensitive and specific to be diagnostic. The
traditional antibodies fail to identify the pathogenic pro-
cesses, organ damage and biological responses to a thera-
peutic intervention. Many groups, including the members
of our laboratory, have found a set of potential biomarkers
for SLE. For example, interferon (IFN)-induced genes and
IFN-inducible chemokines may serve as new biomarkers
for active and severe disease in patients with SLE [40,41].
Some limitations of these biomarkers are revealed grad-
ually, however. Several studies have shown that overex-
pressed transcripts of the type I IFN pathway are also
identified in patients with myositis, RA, Sjögren’s syn-
drome and scleroderma [42-44], so an IFN signature or
chemokine is not sufficiently specific. In two longitudinal
studies to date, researchers have reported conflicting re-
sults on the correlations between type I IFN gene signa-
ture score and diseases activity [45,46]. There is an urgent
need for SLE biomarkers that can help enhance compre-
hension of the mechanisms of diseases or effects of ther-
apies by relating the changes of molecular and cellular
pathways to disease status or clinical responses. In our
present study, we demonstrate that lower expression of
linc0949 is specific for SLE and that it is helpful in identi-
fying disease activity, monitoring disease progression and
guiding therapy. However, linc0949 needs to be further in-
vestigated in large-scale multicenter trials.
On the basis of our present observations, we believe
that linc0949 could be a potentially readily accessible
biomarker useful for diagnosing SLE. As a novel bio-
marker, lincRNAs have the following characteristics. First,
lincRNAs display a wide range of stabilities in the samples
comparable to those of mRNAs of protein-coding genes
[47]. Second, they show a greater tissue specificity com-
pared with protein-coding mRNAs and miRNAs, which
are frequently expressed in multiple tissues, and they show
highly increased or decreased expression levels in disease
[15]. In addition, lincRNAs are also detectible in bodyfluids such as plasma and urine [48-50], diagnostic sam-
ples of which are easy to collect using noninvasive
methods. Moreover, detection of the lincRNAs is simple,
inexpensive and has high throughput, making it a suitable
approach to gaining an overview of disease activity and se-
verity in patients with SLE. These features make lincRNAs
very suitable as biomarkers, and many studies have been
published on this matter in recent years, both in cancer
and in other human diseases such as cardiovascular dis-
eases [50] and neurological disorders [51].
Most lncRNAs described to date have been found to
be related to transcriptional regulation or mRNA pro-
cessing, characteristics that they share with microRNAs.
However, unlike microRNAs, lncRNAs show a greater
complexity of their functions and have a wider spectrum
of biological contexts, such as epigenetic regulation,
enhancer-like function and RNA splicing, editing and
export [52]. In our ongoing experiments, we found that
linc0949 and linc0597 could be induced by TLR2 in
PBMCs of healthy donors, but they did not respond to
the stimuli in patients with SLE as compared with healthy
donors (Figure 5). These results validate that lincRNAs
were indeed involved in the complex regulatory network
of innate immunity. We hypothesized that the regulation
defect of linc0949 and linc0597 could contribute to the
pathogenesis of SLE and that lincRNAs may provide
potential novel strategies for therapeutic intervention,
although their function and mechanism of action need
further exploration.
We have suggested the abnormal expression of linc0949
in patients with SLE, as well as the association of lincRNA
level with disease activity and organ damage; however, in
this study, we did not conduct a functional study of this
lincRNA, and the underlying mechanism needs further in-
vestigation. We did not detect the expression of linc0949
released in the local target tissues and in specific cell sub-
sets in PBMCs. Future studies are needed to investigate
the lincRNA expression level in specific organ and cell
types as well.
Conclusions
We found that the expression of two lincRNAs was dra-
matically reduced in patients with SLE and that the de-
creasing level of linc0949 was correlated with disease
activity, degree of organ damage and medical therapies
in patients with SLE. linc0949 may serve as a potential
biomarker for diagnosis, disease activity and therapeutic
interventions in patients with SLE.Additional file
Additional file 1: Figure S1. Effectiveness of the amplified drugs and
SLEDAI score flare of three patients.
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